Atezolizumab como una realidad en la práctica clínica en carcinoma urotelial

17 / 28

0
5
10
15
20
25
mOS (mo)
ITT
N = 119
IC2/3
n = 32
IC0/1
n = 87
15.9 16.3
10.6
12.3
10.6
14.8
12.3 12.3
NEa,b
15.3
19.1 19.1
Data cutoff date:
Sep
2015
Mar
2016
Jul
2016
Jul
2017
Sep
2015
Mar
2016
Jul
2016
Jul
2017
Sep
2015
Mar
2016
Jul
2016
Jul
2017
17
Overall Survival Over Time
Bold date denotes primary analysis. 95% CIs are plotted as error bars on chart. a Upper 95% CI is NE. b Lower 95% CI is 8.
1-y OS 49% 57% 57% 58% 36% 52% 52% 52% 52% 59% 59% 60%
2-y OS NE NE NE 41% NE NE NE 39% NE NE NE 42%
a
a
a
a
a a a
a
a
Presentado por I Durán et al. GCBC 2018.